Last reviewed · How we verify
Prevention of GVHD
Prevention of GVHD is a Small molecule drug developed by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation. It is currently in Phase 1 development.
At a glance
| Generic name | Prevention of GVHD |
|---|---|
| Sponsor | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant (PHASE2)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevention of GVHD CI brief — competitive landscape report
- Prevention of GVHD updates RSS · CI watch RSS
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation portfolio CI
Frequently asked questions about Prevention of GVHD
What is Prevention of GVHD?
Prevention of GVHD is a Small molecule drug developed by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation.
Who makes Prevention of GVHD?
Prevention of GVHD is developed by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation (see full Association for Training, Education, and Research in Hematology, Immunology, and Transplantation pipeline at /company/association-for-training-education-and-research-in-hematology-immunology-and-tra).
What development phase is Prevention of GVHD in?
Prevention of GVHD is in Phase 1.